Literature DB >> 12421831

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.

Ken Okamoto1, Bryan T Eger, Tomoko Nishino, Shiro Kondo, Emil F Pai, Takeshi Nishino.   

Abstract

TEI-6720 (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid) is an extremely potent inhibitor of xanthine oxidoreductase. Steady state kinetics measurements exhibit mixed type inhibition with K(i) and K(i)' values of 1.2 +/- 0.05 x 10(-10) m and 9 +/- 0.05 x 10(-10) m, respectively. Fluorescence-monitored titration experiments showed that TEI-6720 bound very tightly to both the active and the inactive desulfo-form of the enzyme. The dissociation constant determined for the desulfo-form was 2 +/- 0.03 x 10(-9) m; for the active form, the corresponding number was too low to allow accurate measurements. The crystal structure of the active sulfo-form of milk xanthine dehydrogenase complexed with TEI-6720 and determined at 2.8-A resolution revealed the inhibitor molecule bound in a long, narrow channel leading to the molybdenum-pterin active site of the enzyme. It filled up most of the channel and the immediate environment of the cofactor, very effectively inhibiting the activity of the enzyme through the prevention of substrate binding. Although the inhibitor did not directly coordinate to the molybdenum ion, numerous hydrogen bonds as well as hydrophobic interactions with the protein matrix were observed, most of which are also used in substrate recognition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421831     DOI: 10.1074/jbc.M208307200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.

Authors:  Ken Okamoto; Koji Matsumoto; Russ Hille; Bryan T Eger; Emil F Pai; Takeshi Nishino
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

Review 2.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

3.  3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.

Authors:  Jian-Ming Lü; Qizhi Yao; Changyi Chen
Journal:  Biochem Pharmacol       Date:  2013-08-30       Impact factor: 5.858

4.  Febuxostat.

Authors:  Eliseo Pascual; Francisca Sivera; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

5.  Molybdenum enzymes in higher organisms.

Authors:  Russ Hille; Takeshi Nishino; Florian Bittner
Journal:  Coord Chem Rev       Date:  2011-05-01       Impact factor: 22.315

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Authors:  Bishoy Kamel; Garry G Graham; Kenneth M Williams; Kevin D Pile; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

7.  Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.

Authors:  Seiji Itano; Hiroyuki Kadoya; Minoru Satoh; Takashi Nakamura; Takayo Murase; Tamaki Sasaki; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-21

8.  Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.

Authors:  Caitlin E Cassidy; William N Setzer
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

Review 9.  Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology.

Authors:  Enrico Garattini; Ralf Mendel; Maria João Romão; Richard Wright; Mineko Terao
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

Review 10.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.